Looking for an ivonescimab encore
What similarly acting projects are still unpartnered?
ESMO 2024 preview – Summit could take on Merck in breast cancer
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
One ricochet of the ivonescimab bullet
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
World Lung 2024 – picking apart the Harmoni-2 win
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
ESMO 2024 preview – Summit and BioNTech battle again
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
